Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended March 31, 2026 (Fiscal Year 2026)
Business Overview: Propanc is a development-stage biopharmaceutical company focused on creating non-toxic, long-term cancer therapies to prevent recurrence. Its lead product candidate, PRP, is an enhanced pro-enzyme formulation currently in preclinical development. The company has no commercial revenue and relies on equity and debt financing to fund operations.
Key Financial Metrics
| Metric | Nine Months Ended March 31, 2026 |
Nine Months Ended March 31, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(14,289,468) | $(54,851,839) |
| Net Loss Available to Common Stockholders | $(15,221,714) | $(54,851,839) |
| Cash and Cash Equivalents (Ending) | $443,702 | $50,760 |
| Total Assets | $14,333,780 | $19,631,808 |
| Total Liabilities | $3,505,895 | $5,725,616 |
| Stockholders' Equity | $9,827,885 | $13,906,192 |
| Accumulated Deficit | $(140,843,234) | $(125,621,520) |
| Operating Cash Flow | $(4,080,653) | $(312,982) |
| Financing Cash Flow | $4,473,485 | $418,000 |
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by approximately $40.6 million (74%) compared to the prior nine-month period. This improvement is primarily driven by a massive reduction in non-cash stock-based compensation expenses, which dropped from ~$52.9 million in the prior period to ~$11.6 million in the current period.
- Capital Raising Activities: The company raised significant capital through financing activities, including a public offering of common stock (net proceeds ~$3.3 million), issuance of Series C Preferred Stock (~$950,000), and exercise of Series C warrants ($1.0 million). This contrasts with the prior period where financing proceeds were significantly lower.
- Debt Restructuring and Extinguishment: The company actively repaid and converted various convertible notes and loans. Notable transactions included an exchange agreement with Crown Bridge Partners (settling ~$125k debt for equity) and the conversion of Series C Preferred Stock into common stock. Several related-party loans remain in default.
- Asset Composition: While total assets decreased, cash balances improved significantly from $12,088 to $443,702. However, a substantial portion of current assets ($7.7 million) consists of prepaid expenses, primarily related to stock-based compensation for future services.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Uncertainty: Management explicitly states that the company's losses and cash burn raise substantial doubt about its ability to continue as a going concern for the next 12 months. Continued operations depend on securing additional financing.
- Legal Proceedings: The company is defending a lawsuit filed by Helena Partners, Inc., alleging breach of an engagement agreement and seeking a $250,000 break fee plus a $15,000 deposit. The company intends to vigorously defend the action.
- Debt Defaults: As of March 31, 2026, the company is in default on certain related-party loans totaling $211,545 in principal plus accrued interest. Discussions are ongoing to extend maturity dates.
- Unusual Items:
- Deemed Dividend: A deemed dividend of $932,246 was recorded related to the issuance of Series C Preferred Stock, reducing net income available to common stockholders.
- Warrant Liability: A significant gain of $776,227 was recognized due to the decrease in the fair value of warrant liabilities, driven by the decline in the company's stock price.
- Stock-Based Compensation: Large grants of common stock were issued for services (including a grant of 25.5 million shares valued at $3.57 million), creating significant future dilution and prepaid expense amortization.
- Outlook: The company is advancing its lead asset, PRP, toward a Phase 1b First-In-Human study. Recent developments include new patent filings and a collaboration agreement with Spanish universities for research services.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance of ~$444k is sufficient to fund operations until the next anticipated financing event, given the high burn rate and lack of revenue.
- Dilution Impact: Assess the impact of the 33 million shares currently "issuable" and the 25.5 million shares granted for services on existing shareholder equity.
- Debt Resolution: Confirm the status of negotiations regarding the defaulted related-party loans and the potential for further equity conversion or cash repayment demands.
- Legal Exposure: Monitor the outcome of the Helena Partners lawsuit, specifically the potential liability of $265,000.
- Prepaid Expenses: Scrutinize the $13.8 million in prepaid expenses (current and long-term) to ensure the underlying services are being delivered and the valuation of stock-based prepayments is accurate.